CN113747912B - 重组ccn结构域蛋白和融合蛋白 - Google Patents

重组ccn结构域蛋白和融合蛋白 Download PDF

Info

Publication number
CN113747912B
CN113747912B CN202080023396.5A CN202080023396A CN113747912B CN 113747912 B CN113747912 B CN 113747912B CN 202080023396 A CN202080023396 A CN 202080023396A CN 113747912 B CN113747912 B CN 113747912B
Authority
CN
China
Prior art keywords
seq
protein
proteins
fusion
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080023396.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113747912A (zh
Inventor
阿瓦尔·阿特拉马达
奥勒·约根·卡斯博尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo Universitetssykehus hf
Original Assignee
Oslo Universitetssykehus hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Universitetssykehus hf filed Critical Oslo Universitetssykehus hf
Publication of CN113747912A publication Critical patent/CN113747912A/zh
Application granted granted Critical
Publication of CN113747912B publication Critical patent/CN113747912B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080023396.5A 2019-03-20 2020-03-20 重组ccn结构域蛋白和融合蛋白 Active CN113747912B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19163970.7A EP3711772A1 (en) 2019-03-20 2019-03-20 Recombinant proteins and fusion proteins
EP19163970.7 2019-03-20
PCT/EP2020/057773 WO2020188081A1 (en) 2019-03-20 2020-03-20 Recombinant ccn domain proteins and fusion proteins

Publications (2)

Publication Number Publication Date
CN113747912A CN113747912A (zh) 2021-12-03
CN113747912B true CN113747912B (zh) 2025-04-04

Family

ID=66102364

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080023396.5A Active CN113747912B (zh) 2019-03-20 2020-03-20 重组ccn结构域蛋白和融合蛋白

Country Status (12)

Country Link
US (1) US12606602B2 (https=)
EP (2) EP3711772A1 (https=)
JP (1) JP7600135B2 (https=)
KR (1) KR20210142681A (https=)
CN (1) CN113747912B (https=)
AU (1) AU2020243073B2 (https=)
BR (1) BR112021017147A2 (https=)
CA (1) CA3133740A1 (https=)
IL (1) IL285930B2 (https=)
MX (1) MX2021011407A (https=)
SG (1) SG11202109738QA (https=)
WO (1) WO2020188081A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023552810A (ja) * 2020-12-08 2023-12-19 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 抗ｅｇｆｒキメラ抗原受容体
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
GB202400055D0 (en) * 2024-01-03 2024-02-14 Tribune Therapeutics Ab Use of ccn domain-containing proteins for the treatment of disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1999047556A2 (en) * 1998-03-19 1999-09-23 Trustees Of Tufts College Novel heparin-induced ccn-like molecules and uses therefor
EP1326980B1 (en) * 2000-10-16 2008-03-19 Genentech, Inc. Methods of treatment using wisp polypeptides
CN1835763B (zh) 2003-06-20 2011-04-20 妙甯公司 Ccn1组合物和方法
FR2858234B1 (fr) 2003-08-01 2007-09-14 Centre Nat Rech Scient Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
ATE506961T1 (de) * 2005-01-10 2011-05-15 Univ Rosalind Franklin Medicine & Science Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen
CN101146826A (zh) 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US20080207489A1 (en) 2007-02-21 2008-08-28 John Castellot Use of CCN5 for treatment of smooth muscle proliferation disorders
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
DK3061817T3 (en) * 2009-04-30 2019-03-04 Kao Corp Alkaline protease variants
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
JP5820378B2 (ja) * 2009-09-09 2015-11-24 ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
JP5939584B2 (ja) 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 治療用ｃｃｎ３ペプチドおよびそれらの類似体
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
PT2621515T (pt) * 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
ES2623912T3 (es) 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
WO2014008582A1 (en) 2012-07-11 2014-01-16 The University Of Western Ontario Method of treating wounds with penostin and/or ccn2
US20140271641A1 (en) 2013-03-14 2014-09-18 University Of Guelph Thrombospondin-1 polypeptides and methods of using same
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
AU2016228806B2 (en) 2015-03-12 2020-10-22 Medimmune, Llc Method of purifying albumin-fusion proteins
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)
CA3011887C (en) 2016-03-14 2024-10-29 Universitetet I Oslo Genetically transformed immunoglobulins with altered FCRN binding
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
US11795202B2 (en) 2016-08-04 2023-10-24 Stichting Vumc Fusion polypeptide comprising a foreign antigen and self antigen
US20180127478A1 (en) 2016-09-16 2018-05-10 Wei-Chiang Shen SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY
KR20180099537A (ko) * 2017-02-28 2018-09-05 주식회사 파이안바이오테크놀로지 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제
KR102008407B1 (ko) 2017-09-05 2019-08-08 한국생명공학연구원 코돈 최적화된 il-21 및 이의 용도
WO2019071007A1 (en) 2017-10-05 2019-04-11 New York Genome Center, Inc. METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM

Also Published As

Publication number Publication date
IL285930B1 (en) 2024-09-01
CN113747912A (zh) 2021-12-03
EP3941507A1 (en) 2022-01-26
BR112021017147A2 (pt) 2021-11-09
SG11202109738QA (en) 2021-10-28
JP7600135B2 (ja) 2024-12-16
CA3133740A1 (en) 2020-09-24
AU2020243073B2 (en) 2025-06-05
US20220144903A1 (en) 2022-05-12
EP3711772A1 (en) 2020-09-23
IL285930B2 (en) 2025-01-01
US12606602B2 (en) 2026-04-21
MX2021011407A (es) 2022-01-24
IL285930A (en) 2021-10-31
KR20210142681A (ko) 2021-11-25
AU2020243073A1 (en) 2021-11-11
JP2022525661A (ja) 2022-05-18
WO2020188081A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
EP3027642B1 (en) Growth differentiation factor 15 (gdf-15) constructs
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
EP2858662B1 (en) Fibroblast growth factor 21 proteins
CN100390201C (zh) 具有增强红细胞生成素体内活性的融合蛋白
KR20190129896A (ko) Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
JP2634323B2 (ja) Ｔｃｆ‐▲ｉｉ▼のアミノ酸配列をコードするｄｎａを含むプラスミド，形質転換細胞及びこれを用いて生理活性物質を生産する方法
CN113747912B (zh) 重组ccn结构域蛋白和融合蛋白
CN104293834A (zh) GLP-1或其类似物与抗体Fc片段融合蛋白的制备方法
US20170334971A1 (en) Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
CN113968911A (zh) 胰岛素-Fc融合蛋白及其应用
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
US20220348623A1 (en) Stabilized proteolytically activated growth differentiation factor 11
CN116948037A (zh) 一种新结构长效卵泡刺激素重组蛋白及其制备和应用
KR20180003677A (ko) 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
WO2008014054A2 (en) Bmp-7 variant compositions, methods and uses
CN113527506A (zh) 融合蛋白及其应用
CN108424459A (zh) 人血清白蛋白与人突变型肝细胞生长因子的融合蛋白及其制备方法和应用
RU2797464C2 (ru) Слитые молекулы эктодомена рецептора tgf-бета и их применения
HK1225738B (en) Growth differentiation factor 15 (gdf-15) constructs
WO2015161832A1 (zh) 长效重组人干扰素α2b-Fc融合蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant